OTSKY - Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data Candidate Reduces Agitation Compared To Placebo | Benzinga
Wednesday, IGC Pharma Inc (NYSE:IGC) announced the results of an interim analysis of its ongoing Phase 2 trial of IGC-AD1 for Agitation in Dementia from Alzheimer’s Disease (AAD).
The interim data demonstrates a clinical and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease.
The study’s primary goal is to assess the change in AAD after six weeks using a standard scale, the Cohen Mansfield Agitation Inventory (CMAI).
Based on interim data, patients taking IGC-AD1, on average, experienced a more significant reduction in agitation scores compared to those on placebo, and the positive effects were observed as early as week two of the trial.
At ...